National Institutes of Health
Genomic and Biologic Therapies for ADRD (U01 Clinical Trial Optional)
Genomic and Biologic Therapies for ADRD (U01 Clinical Trial Optional) is a funding opportunity from National Institutes of Health, closing October 10, 2028.
Overview
This Notice of Funding Opportunity (NOFO) supports the translation of genome editing and other biologic therapies for Alzheimer's Disease-Related Dementias (ADRD). The program spans the full translational pipeline, from therapeutic lead optimization and drug product development through IND-enabling studies and early…